{
  "id": "mhgap#risk_safety_50bf9363",
  "content": "y Most ASMs are associated with higher risks of major ASM exposure exclusively through breast-milk. It\ncongenital malformations in offspring of women is, though, noted that the amount of ASM in breast-\ntaking these medicines during pregnancy compared milk is extremely low and that the baby will likely\nwith controls who were not taking an ASM. have been exposed to the same ASM(s) in higher\ny The highest risks of major (OR = 2.93; 95% CI: 2.36 to concentration while in utero.\n3.69) and minor (OR = 17.76; 95% CI: 1.60 to 633.30)\nImplementation considerations\ncongenital malformation were reported in infants of\nwomen taking sodium valproate. y The choice of medicine is affected by a number of\nfactors, including seizure semiology, comorbidities,\ny Phenobarbital, phenytoin and carbamazepine were\navailability, cost and side-effects.\nalso associated with higher risks of major and minor\ncongenital malformations. y Women and girls of childbearing potential who\nare prescribed sodium valproate should be\ny Topiramate was associated with higher risks of\nadvised to use effective contraception without\nmajor congenital malformations with no information\ninterruption, for the entire duration of treatment.\non minor congenital malformations available.\nFurther information on contraception is available",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "risk_safety",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General â€” Risk Safety y Most ASMs are associated with higher risks of major ASM exposure exclusively through breast-milk. It\ncongenital malformations in offspring of women is, though, noted that the amount of ASM in breast-\ntaking these medicines during pregnancy compared milk is extremely low and that the baby will likely\nwith controls who were not taking an ASM. have been exposed to the same ASM(s) in higher\ny The highest risks of major (OR = 2.93; 95% CI: 2.36 to concentration while in utero.\n3.69) and minor (OR = 17.76; 95% CI: 1.60 to 633.30)\nImplementation considerations\ncongenital malformation were reported in infants of\nwomen taking sodium valproate. y The choice of medicine is affected by a number of\nfactors, including seizure semiology, comorbidities,\ny Phenobarbital, phenytoin and carbamazepine were\navailability, cost and side-effects.\nalso associated with higher risks of major and minor\ncongenital malformations. y Women and girls of childbearing potential who\nare prescribed sodium valproate should be\ny Topiramate was associated with higher risks of\nadvised to use effective contraception without\nmajor congenital malformations with no information\ninterruption, for the entire duration of treatment.\non minor congenital malformations available.\nFurther information on contraception is available Y most asms are associated with higher risks of major asm exposure exclusively through breast-milk. it\ncongenital malformations in offspring of women is, though, noted that the amount of asm in breast-\ntaking these medic..."
}